Caribou Biosciences launches CB-010 GALLOP Phase 1 trial in lupus

Caribou Biosciences, Inc., a clinical-stage leader in CRISPR genome-editing biopharmaceuticals, has announced the initiation of its CB-010 GALLOP Phase 1 clinical trial for patients with ... Read More